We often ignore stomach pain by saying that it might be due to gas or that we might have eaten too much. However, it is a ...

In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of ...